Omico is providing free Comprehensive Genomic Profiling (CGP) to patients with advanced, incurable or an earlier diagnosis of a poor prognosis cancer, to identify potential matches to clinical trials with new targeted therapies.
Omico is also attracting more international precision oncology trials to Australia to increase treatment options for patients.
Get help finding and triaging trial options for your patients.
Access comprehensive genomic profiling at no cost to your patient to identify clinical trials and treatments specific to your patient’s cancer sub-type.
Get faster, curated and qualified recommendations.
Get support setting up clinical trials that may have previously been impossible due to low patient numbers.
Appropriate patients with later-stage cancer that is not responding to current treatment or at high-risk for cancer (due to hereditary conditions):
Traditionally, biomarker screening is performed in each individual clinical trial. This inefficient method contributes significant costs to running a clinical trial, costing in the region of AUD $10M to identify 200 trial participants.
CGP is a next-generation screening approach that looks for hundreds of cancer biomarkers for multiple trials all at the same time. This more efficient method costs in the region of AUD $10 M to identify 400 trial participants for multiple clinical trials, a significant cost saving.
Our Cancer Screening Program (CaSP) brings comprehensive genomic profiling to patients with advanced and incurable cancer and helping identify potential treatments or clinical trials.
Our Molecular Screening and Therapeutics (MoST) study aims to characterise molecular changes in a patient’s cancer that may help to identify a targeted therapy or clinical trial.
We’re examining the genetic basis of inherited cancer with our Genetic Cancer Risk in the Young (RisC) study.
Our Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) study is investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer.
If your patient is eligible for the screening program we will:
If you answer “yes” to the following statements your patient may be eligible for enrolment.
Your patient:
To get your patient onto CaSP you will need to:
Omico facilitates a nationwide network of research and treatment centres that facilitate, support and promote genomic cancer medicine.